Antibody Information
General Information of This Antibody
| Antibody ID | ANI0CXLFD |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | SYD1594 |
|||||
| Synonyms |
HC-P41C
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Human IgG1-kappa |
|||||
| Antigen Name | Trophoblast glycoprotein (TPBG) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
The Activity Data of This Antibody
| Antibody Activity Information 1 | [1] | |||||
|
Dissociation Constant (Kd)
|
0.2
|
nM
|
||||
|---|---|---|---|---|---|---|
| Antibody Function | Confirm the effect of the drug conjugation with the anti-5T4 mAb on binding activity to target. | |||||
| Antibody Antigen Binding Assay | Observed binding affinities for SYD1875 and its unconjugated antibody SYD1594 with 5T4 antigen on sensor surface using SPR. | |||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SYD1875 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Inclusion: Histologically-confirmed advanced/metastatic cancer (Part 1: any solid tumor; Part 2: 3 predefined cohorts) with 5T4 membrane staining, ECOG ≤1, adequate organ function (Part 2 requires measurable disease). Exclusion: Prior 5T4/SYD985 therapy, recent anticancer/hormone therapy (4w/1w), active keratitis/significant organ dysfunction, symptomatic brain metastases or treatment within 8w.
Click to Show/Hide
|
||||
| Administration Dosage |
SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04202705 | Clinical Status | PHASE1 | ||
| Clinical Description |
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With 5T4-expressing Locally Advanced or Metastatic Solid Tumours
|
||||
| Primary Endpoint |
Incidence of dose-limiting toxicities
|
||||
| Other Endpoint |
Objective response rate
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04202705 | Clinical Status | Phase 1 | ||
| Clinical Description |
A first-in-human dose-escalation and expansion study with the antibody-drug conjugate SYD1875 to evaluate the safety, pharmacokinetics and efficacy in patients with 5T4-expressing locally advanced or metastatic solid tumours.
|
||||
References